Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibuprofen + hyoscine butylbromide for primary dysmenorrhea pain
2022-000843-57Phase 3Terminated
- Sponsor
- Rontis
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in primary dysmenorrhea (PD) comparing Ibuprofen + hyoscine butylbromide, Ibuprofen alone and Hyoscine butylbromide alone (3 arms). Primary endpoint: AUC0-4h for pain intensity difference after each of the first two doses. Started Aug 2022; status: terminated.
02
Drugs
ibuprofenhyoscine butylbromide
03
Conditions
primary dysmenorrhea (PD)
Beyond the preview
Go deeper on 2022-000843-57.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000843-57.